Sign in
Taking people in United StatesNo phase

QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry

Key facts

Who runs it
SeaStar Medical
Where
Ann Arbor, Atlanta, Birmingham, Chicago, Cincinnati, Cleveland, Dallas, Denver, Fort Worth, Houston, Nashville, Palo Alto, Philadelphia, and San Francisco, United StatesSee the 15 sites
Trial code
Status
Recruiting
People taking part
50 people, planned
Started
19 Jul 2024
Planned end
Aug 2026
Type of study
Observational
Treatments tested
  • QUELIMMUNE (SCD-PED)
Record updated
14 May 2026

Who can take part

Age
Up to 22 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • All patients initiated on QUELIMMUNE therapy under the HDE-approved indication

Who cannot take part

  • Known allergy to any components of QUELIMMUNE
  • Age >22 years
  • Weight <10kg

Where in United States

  • CS Mott Children's HospitalAnn Arbor, United StatesContact: Mohamed Zidan, MDTaking people
  • Children's Hospital of Atlanta - Arthur M. BlankAtlanta, United StatesContact: Mohamed Zidan, MDTaking people
  • Children's Hospital of Atlanta - Scottish RiteAtlanta, United StatesContact: Mohamed Zidan, MDTaking people
  • Children's of AlabamaBirmingham, United StatesContact: Mohamed Zidan, MDTaking people
  • Lurie Children's Hospital of ChicagoChicago, United StatesContact: Mohamed Zidan, MDTaking people
  • Cincinnati Children's HospitalCincinnati, United StatesContact: Mohamed Zidan, MDTaking people
  • Cleveland Clinic Children's HospitalCleveland, United StatesContact: Mohamed Zidan, MDTaking people
  • Children's Medical Center DallasDallas, United StatesContact: Mohamed Zidan, MDTaking people
  • HealthONE HCA Rocky Mountain Children's HospitalDenver, United StatesContact: Mohamed Zidan, MDTaking people
  • Cook Children's HospitalFort Worth, United StatesContact: Mohamed Zidan, MDTaking people
  • Texas Children's HospitalHouston, United StatesContact: Mohamed Zidan, MDTaking people
  • Monroe Carrell Jr. Children's Hospital at VanderbiltNashville, United StatesContact: Mohamed Zidan, MDTaking people
  • Lucile Packard Children's Hospital - StanfordPalo Alto, United StatesContact: Mohamed Zidan, MDTaking people
  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Mohamed Zidan, MDTaking people
  • UCSF (Benioff Children's)San Francisco, United StatesContact: Mohamed Zidan, MDTaking people

About the trial

What the trial wants to find out

QUELIMMUNE is FDA-approved under an HDE for the treatment of pediatric patients (weight ≥10kg and age ≤22 years) with AKI due to sepsis or a septic condition on antibiotic therapy and requiring RRT.

Read full original descriptionShow less

The purpose of this surveillance registry is to prospectively collect safety data among all patients treated with QUELIMMUNE under the HDE. More specifically, we intend on comparing the incidence of new (secondary) blood stream infections in the first 28 days after SCD-PED initiation to a comparator group of matched CKRT patients with sepsis who did not receive treatment with QUELIMMUNE

The group in the trial

  • QUELIMMUNE Surveillance Registry Participants

    All patients treated with the QUELIMMUNE device as a part of clinical practice under the approved HDE indication must be included in this registry.

    Treatment: QUELIMMUNE (SCD-PED)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pediatric Selective Cytopheretic Device (SCD-PED, QUELIMMUNE) for Critically Ill Children With Acute Kidney Injury: A Humanitarian Device Exemption (HDE) Surveillance Registry Protocol
Record updated
14 May 2026